Guo JY, Dong XY, Li S, Tang JF, Zhou CF. Chinese patent medicine: Opening new perspectives for treatment of post-endoscopic submucosal dissection esophageal stricture in esophageal cancer patients. World J Gastroenterol 2025; 31(14): 102943 [DOI: 10.3748/wjg.v31.i14.102943]
Corresponding Author of This Article
Ce-Fan Zhou, PhD, Professor, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 14, 2025; 31(14): 102943 Published online Apr 14, 2025. doi: 10.3748/wjg.v31.i14.102943
Chinese patent medicine: Opening new perspectives for treatment of post-endoscopic submucosal dissection esophageal stricture in esophageal cancer patients
Jie-Yu Guo, Xue-Ying Dong, Shi Li, Jing-Feng Tang, Ce-Fan Zhou
Jie-Yu Guo, School of Life and Health Sciences, Institute of Biomedical Research, Wuhan 430068, Hubei Province, China
Xue-Ying Dong, Shi Li, Jing-Feng Tang, Ce-Fan Zhou, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, Wuhan 430068, Hubei Province, China
Author contributions: Guo JY wrote the original draft; Guo JY and Zhou CF participated in drafting the manuscript; Dong XY, Li S, and Tang JF provided some opinions; Zhou CF contributed to conceptualization, writing, reviewing, and editing; all authors have read and approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82370715, No. 32270768, and No. 82273970; National Key R and D Program of China, No. 2023YFC2507904; and Innovation Group Project of Hubei Province, No. 2023AFA026.
Conflict-of-interest statement: The authors declare no conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ce-Fan Zhou, PhD, Professor, National "111" Center for Cellular Regulation and Molecular Pharmaceutics, School of Life and Health Sciences, Key Laboratory of Fermentation Engineering (Ministry of Education), Hubei University of Technology, No. 28 Nanli Road, Wuhan 430068, Hubei Province, China. cefan@hbut.edu.cn
Received: November 4, 2024 Revised: February 28, 2025 Accepted: March 10, 2025 Published online: April 14, 2025 Processing time: 159 Days and 13.9 Hours
Abstract
Endoscopic submucosal dissection (ESD) is an effective technique for treating early esophageal cancer, and the prevention of postoperative esophageal stricture has emerged as a significant research topic. Zhou et al utilized an experimental minipig model to demonstrate that Kangfuxin (KFX) can improve postoperative esophageal stricture following ESD by inhibiting transforming growth factor-β1-driven fibrosis and the downstream fibrotic mediators Smad2/3. In this letter, we primarily discuss recent advancements in the treatment of esophageal stricture, the clinical applications of KFX, and the mechanisms involved in alleviating postoperative esophageal stricture, aiming to provide insights for advancing clinical practice and research in esophageal stricture after ESD.
Core Tip: Post-endoscopic submucosal dissection esophageal stricture significantly affects patients' quality of life; however, current treatment options are inadequate to meet clinical demands. In this letter, we first examine the limitations of existing treatment methods for esophageal stricture. We then introduce the novel therapeutic agent Kangfuxin solution and elucidate its mechanisms of action. Finally, we explore some emerging treatment technologies and propose potential avenues for future research.
